NL300169I1 - Farmaceutische formulering. - Google Patents

Farmaceutische formulering.

Info

Publication number
NL300169I1
NL300169I1 NL300169C NL300169C NL300169I1 NL 300169 I1 NL300169 I1 NL 300169I1 NL 300169 C NL300169 C NL 300169C NL 300169 C NL300169 C NL 300169C NL 300169 I1 NL300169 I1 NL 300169I1
Authority
NL
Netherlands
Prior art keywords
pct
date
pharmaceutical formulation
sec
active agent
Prior art date
Application number
NL300169C
Other languages
English (en)
Original Assignee
Neopharma Production
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharma Production filed Critical Neopharma Production
Publication of NL300169I1 publication Critical patent/NL300169I1/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL300169C 1992-11-30 2005-01-03 Farmaceutische formulering. NL300169I1 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Publications (1)

Publication Number Publication Date
NL300169I1 true NL300169I1 (nl) 2005-03-01

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300169C NL300169I1 (nl) 1992-11-30 2005-01-03 Farmaceutische formulering.

Country Status (15)

Country Link
US (1) US5635213A (nl)
EP (1) EP0670713B3 (nl)
JP (1) JP3661703B2 (nl)
AT (1) ATE184191T3 (nl)
AU (1) AU688290B2 (nl)
CA (1) CA2150464C (nl)
DE (2) DE122005000021I1 (nl)
DK (1) DK0670713T3 (nl)
ES (1) ES2137350T7 (nl)
FR (1) FR04C0024I2 (nl)
GR (1) GR3031988T3 (nl)
NL (1) NL300169I1 (nl)
NZ (1) NZ258276A (nl)
SE (1) SE9203594D0 (nl)
WO (1) WO1994012153A1 (nl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
PL1708790T3 (pl) * 2003-12-02 2010-10-29 Pharmaneuroboost N V Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
CA2653683A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
PL3782617T3 (pl) 2014-09-04 2024-06-24 Lobsor Pharmaceuticals Aktiebolag Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
PT3209302T (pt) 2014-10-21 2019-07-19 Abbvie Inc Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP3291872A4 (en) 2015-05-06 2019-02-13 SynAgile Corporation PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US20180021280A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and Carbidopa Intestinal Gel and Methods of Use
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
WO2019166322A1 (en) 2018-03-02 2019-09-06 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
DK0670713T3 (da) 2000-03-20
NZ258276A (en) 1996-09-25
AU688290B2 (en) 1998-03-12
EP0670713A1 (en) 1995-09-13
CA2150464C (en) 2002-02-05
DE69326350T2 (de) 2000-01-27
JPH08504764A (ja) 1996-05-21
DE69326350T3 (de) 2018-01-11
FR04C0024I2 (nl) 2010-12-31
ES2137350T3 (es) 1999-12-16
WO1994012153A1 (en) 1994-06-09
US5635213A (en) 1997-06-03
DE122005000021I1 (de) 2006-02-23
EP0670713B1 (en) 1999-09-08
ES2137350T7 (es) 2017-11-13
GR3031988T3 (en) 2000-03-31
FR04C0024I1 (nl) 2004-03-12
AU5583694A (en) 1994-06-22
DE69326350D1 (de) 1999-10-14
JP3661703B2 (ja) 2005-06-22
EP0670713B3 (en) 2016-10-05
ATE184191T3 (de) 1999-09-15
CA2150464A1 (en) 1994-06-09
SE9203594D0 (sv) 1992-11-30

Similar Documents

Publication Publication Date Title
DK0670713T3 (da) Farmaceutisk formulering
ES2115945T3 (es) Preparaciones topicas cosmeticas y medicinales.
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ES2091012T3 (es) Preparacion y utilizacion de nuevos sistemas coloidales dispersables a base de ciclodextrina, en forma de nanoesferas.
ATE162725T1 (de) Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
MX9304530A (es) Suministro topico mejorado de farmacos.
MY101791A (en) New benzimidazole derivatives
TW347339B (en) Oral delivery of discrete units
ATE241990T1 (de) 3-beta-hydroxylierte natürliche steroidderivate enthaltende arzneimittelzusammensetzungen und ihre verwendung
ATE333867T1 (de) Emulgierte arzneistoffabgabesysteme
FI970788A (fi) Kasveilla käytettäviksi tarkoitettuja suihkutettavissa olevia, kalvon muodostavia järjestelmiä vaikuttavien aineiden antamiseksi
DE69524772D1 (de) Ophthalmologisches abgabesystem
ATE192921T1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
ES2052016T3 (es) Composicion emulsionada.
MX9307256A (es) Dispositivo de administracion que tiene excipientes capsulados.
IE873125L (en) Benzimidazole derivatives
DE69129696D1 (de) Polymeres arzneimittelabgabesystem
ATE175867T1 (de) Ophthalmologische zubereitungen
MY102411A (en) Nasal solutions
HRP20020332B1 (en) Oral solution containing galanthamine and a sweetening agent
ES2193562T3 (es) Dispositivo de dosificacion.
DE59408645D1 (de) Lactulose-pastillen
MX9302272A (es) Retinoides solubles en agua.
DE59406568D1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)